Glenmark Pharmaceuticals Overview

  • Founded
  • 1977
Founded
  • Status
  • Public
  • Employees
  • 11,226
Employees
  • Stock Symbol
  • 532296
Stock Symbol
  • Investments
  • 6
  • Share Price
  • $8.18
  • (As of Friday Closing)

Glenmark Pharmaceuticals General Information

Description

Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address the unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
BOM
Primary Office
  • Glenmark House, B. D. Sawant Marg
  • Chakala, Off Western Express Highway, Andheri (East)
  • Mumbai, Maharashtra 400099
  • India
+91 022 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Glenmark Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.18 $7.95 $5.83 - $9.26 $2.31B 282M 176K $0.46

Glenmark Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020 FY 2019 31-Mar-2019
EV 2,045,144 2,045,144 1,107,488 2,992,090
Revenue 1,452,425 1,452,425 1,463,358 1,386,588
EBITDA 292,896 292,896 266,087 279,804
Net Income 130,388 130,388 109,214 132,156
Total Assets 2,124,502 2,124,502 1,947,071 1,914,440
Total Debt 599,331 599,331 687,613 640,564
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Glenmark Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Glenmark Pharmaceuticals‘s full profile, request access.

Request a free trial

Glenmark Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and developme
Pharmaceuticals
Mumbai, India
11,226 As of 2020
00000
000000000 00000

0000000

boris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate v
000000000000000
New Delhi, India
000 As of 0000

0000000

amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
0000 000000000
Ahmedabad, India
00000 As of 0000
0000
0.000 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Glenmark Pharmaceuticals Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Panacea Biotec Angel-Backed New Delhi, India 000
0000000 0000000000 Corporation Ahmedabad, India 00000 0000 00000000000 0000
00000 Corporation Mumbai, India 00000 00000000
00000 000000000000 Private Equity-Backed Ahmedabad, India 0000 000.00 000000 - 000 000.00
000000000000000 Corporation Brentford, United Kingdom 000000 000000000
You’re viewing 5 of 29 competitors. Get the full list »

Glenmark Pharmaceuticals Executive Team (18)

Name Title Board Seat Contact Info
Glenn Saldanha Chief Executive Officer, Chairman & Managing Director
Jayaram Philkana President & Global Chief Human Resources Officer
Darshan Makhey President & Chief Quality Officer
V. S. Mani Board Member, Executive Director & Chief Financial Officer
D.R. Mehta Board Member & Independent Director
You’re viewing 5 of 18 executive team members. Get the full list »

Glenmark Pharmaceuticals Board Members (10)

Name Representing Role Since
0. 0. 00000000 Glenmark Pharmaceuticals Board Member & Non-Executive Director 000 0000
0000000 00000 00.0 Self Board Member & Independent Director 000 0000
00000 0000000 00.0 Self Board Member 000 0000
000000 00000 Glenmark Pharmaceuticals Executive Director - Corporate Services& Board Member 000 0000
00000000 0000000000000 Self Board Member & Independent Director 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Glenmark Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glenmark Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Glenmark Pharmaceuticals‘s full profile, request access.

Request a free trial

Glenmark Pharmaceuticals Investments & Acquisitions (6)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 000000000000 16-Jul-2018 000000000000000000 Distributors/Wholesale
00000000000 26-Mar-2007 000000000000000000 Drug Discovery
000000 00000000 26-Dec-2005 000000000000000000 Other Pharmaceuticals and Biotechnology 00000 00000000
0000 0000000000000 22-Dec-2005 00000 00000 00 00.000 Drug Discovery
Servycal 26-Oct-2005 Merger/Acquisition Specialty Retail 00000 00000000
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

Glenmark Pharmaceuticals Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000 0000000000000 22-Dec-2005 00000 00000 00 00.000 Completed
  • 4 buyers
To view Glenmark Pharmaceuticals’s complete exits history, request access »